Pharmaceutical Key Opinion Leader Management

Effective Strategies for Segmenting Thought Leaders

Pharmaceutical Key Opinion Leader Management

$1,995.00 $995.00

As the number of available Pharmaceutical Key Opinion Leaders (KOLs) dwindles due to increased regulatory mandates and institutional restrictions on physician-pharma relationships, finding the right thought leaders becomes increasingly important. Use the report to create centralized KOL development teams to identify, recruit and manage relationships with top KOLs. Set criteria to pinpoint up-and-coming thought leaders at the global, national and regional level. Benchmark extensive thought leader segmentation data split by KOL tier, company size and 26 individual therapeutic areas.

  • Description
  • Additional information

REPORT HIGHLIGHTS

This pharmaceutical key opinion leaders study is designed to help medical affairs teams implement KOL development teams to identify and recruit thought leaders and to manage and track relationships. The report’s contents include:

Pharmaceutical Key Opinion Leader Management: Effective Strategies for Segmenting Thought Leaders

  • Publication Date: May 2013
  • 179 Pages
  • Chapters:4 + an Executive Summary
  • Metrics: 500+
  • Charts/Graphics: 95+

Data have been split by team region:

  • Global
  • US
  • European Country-Level

Data have also been split by company size:

  • Large pharma
  • Mid-size pharma
  • Small pharma
  • Medical Device pharma
Report Features

Leverage internal and external expertise to pinpoint up-and-coming pharmaceutical key opinion leaders at all levels of geographic influence. Track the number of KOL relationships companies maintain at the global level, as well as within the US and Europe to benchmark your team’s needs. Prepare companywide KOL pools that thrive even after the Sunshine Act’s full implementation. Explore profiles other top-performing thought leader development teams to structure and right-size your group.

Reason to Buy

Compare Tier 1, 2 and 3 profiles for pharmaceutical key opinion leaders across a wide range of data splits, including five company types and 26 individual therapeutic areas. Examine the most common segmentation criteria among top-performing pharmaceutical companies, including number of publications, years of clinical experience, speaking ability and much more. Weigh the importance of specific criteria in influencing KOL segmentation and fair-market value decisions.

Target Audience

Life science company executives, directors, and managers involved in the following areas should consider purchasing this report:
– Medical affairs
– Thought leader development
– Key opinion leader management
– Thought leader segmentation
– External expert identification
– Medical science liaison (MSL) programs

Chapter Example

Across the 24 companies surveyed, 75% report using databases to manage thought leader relationships (Figure 2.23). Among those reporting database usage, most companies (69%) report using a proprietary customer relationship management system (CRM) rather than either an off-the-shelf CRM software or an Excel spreadsheet (Figure 2.24). With the release of the final version of the Sunshine Act, companies are busy deciphering the legislation’s meaning and trying to understand its application across state and national levels. As a result, many companies are placing additional emphasis on their CRM and other database technology. These organizations are more closely monitoring how and to what degree they track KOL engagement levels. Large pharmaceutical companies may have formal guidelines for database operations, whereas protocols at smaller pharmaceutical or biotech companies may be less formal. Company B’s team relies on a functional draft document that outlines procedures for updating and maintaining its proprietary CRM system.